Manufacturer of Controlled Substances; Notice of Application, 30418 [E8-11631]
Download as PDF
<![CDATA[
30418
Federal Register / Vol. 73, No. 102 / Tuesday, May 27, 2008 / Notices
your entire comment—including your
personal identifying information—may
be made publicly available at any time.
While you can ask us in your comment
to withhold your personal identifying
information from public review, we
cannot guarantee that we will be able to
do so.
Dated: May 20, 2008.
Gary D. Cooper,
District Manager.
[FR Doc. E8–11722 Filed 5–23–08; 8:45 am]
BILLING CODE 4310–GG–P
DEPARTMENT OF THE INTERIOR
Minerals Management Service
Extension of Post-Sale Evaluation
Period for Central Gulf of Mexico
Lease Sale 206
Minerals Management Service
(MMS), Interior.
ACTION: Notice to Extend Post-Sale
Evaluation Period for Central Gulf of
Mexico Lease Sale 206.
AGENCY:
SUMMARY: This notice extends by 30
days, the post-sale evaluation period for
Central Gulf of Mexico Lease Sale 206.
The Minerals Management Service
(MMS) will complete evaluating all the
bids received in this sale by July 17,
2008. This action is necessary due to the
unusually high number of bids received
in this lease sale.
DATES: The post-sale evaluation period
ends on June 17, 2008.
FOR FURTHER INFORMATION CONTACT:
David Marin, Regional Supervisor,
Resource Evaluation, Gulf of Mexico
Region, telephone 504–736–2710.
SUPPLEMENTARY INFORMATION: In the
Central Gulf of Mexico Sale 206, held
March 19, 2008, we received 1057 bids
on 615 tracts, 513 tracts of which passed
to a second phase requiring additional
detailed evaluations. The aggressive
bidding activity is due, in part, to the
high number of quality prospects on
recently expired unexplored tracts in
newly established deepwater
hydrocarbon plays and to the cost
saving technological advances related to
hydrocarbon exploration and
development in the Gulf of Mexico’s
deepwater environment. The unusually
high number of bids received on a large
number of tracts, and the high volume
of exclusively reprocessed data
identified on Sale 206, significantly
increases the workload for reviewing the
adequacy of bids. Consequently, MMS is
unable to conduct and complete the bid
review process within the 90 days, i.e.,
by June 17, 2008. Under the provisions
of § 256.47(e)(2), MMS is extending the
bid evaluation period until July 17,
2008.
Dated: May 5, 2008.
Lars Herbst,
Regional Director, Gulf of Mexico OCS Region.
[FR Doc. E8–11711 Filed 5–23–08; 8:45 am]
substance intermediates for sale to its
customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 28, 2008.
BILLING CODE 4310–MR–P
Dated: May 15, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–11631 Filed 5–23–08; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 25, 2008,
Siegfried (USA), Inc., Industrial Park
Road, Pennsville, New Jersey 08070,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Oripavine(9330), a basic class of
controlled substance listed in schedule
II.
The company will use the above
listed controlled substance in the
manufacture of other controlled
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 21,
2007, AMRI Rensselaer, Inc., 33
Riverside Avenue, Rensselaer, New
York 12144, made application by
renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
pwalker on PROD1PC71 with NOTICES
Marihuana (7360) ......................................................................................................................................................
Tetrahydrocannabinols (7370) ...................................................................................................................................
Amphetamine (1100) .................................................................................................................................................
Lisdexamfetamine (1205) ..........................................................................................................................................
Methylphenidate (1724) .............................................................................................................................................
Pentobarbital (2270) ..................................................................................................................................................
Hydrocodone (9193) ..................................................................................................................................................
Meperidine (9230) ......................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage form) (9273) ..............................................................................................
Oxymorphone (9652) .................................................................................................................................................
Fentanyl (9801) ..........................................................................................................................................................
The company plans to manufacture
bulk controlled substances for use in
product development and for
VerDate Aug<31>2005
17:22 May 23, 2008
Jkt 214001
distribution to its customers. In
reference to drug code 7360
(Marihuana), the company plans to bulk
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
I
I
II
II
II
II
II
II
II
II
II
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
E:\FR\FM\27MYN1.SGM
27MYN1
]]>Agencies
[Federal Register Volume 73, Number 102 (Tuesday, May 27, 2008)]
[Notices]
[Page 30418]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-11631]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on April 25, 2008, Siegfried
(USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made
application by letter to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Oripavine(9330), a basic class
of controlled substance listed in schedule II.
The company will use the above listed controlled substance in the
manufacture of other controlled substance intermediates for sale to its
customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 28, 2008.
Dated: May 15, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-11631 Filed 5-23-08; 8:45 am]
BILLING CODE 4410-09-P
